Higher Learning for Sales Reps

June 2009
Pharmaceutical Representative;Jun2009, Vol. 39 Issue 6, p8
The article reports on the new educational initiative in hypertension and cardiovascular disease designed by the American Society of Hypertension (ASH) in the U.S. The educational program aims to enhance the educational level of allied health professionals and sales representatives of the pharmaceutical industry. Sales representatives are expected to undergo training for around 10 hours of home study before attending the live course.


Related Articles

  • Working with Academia. Deitch, Mark; Sutherland, Deborah M. // Pharmaceutical Executive;Oct2003 Supplement, Vol. 23, p28 

    University medical schools and hospitals can be pharmaceuticals' best allies in the quest for credible, well attended continuing medical education (CME) programs. In this article, the authors provide a detailed blueprint for industry-academic collaborations, which is considered one of the most...

  • The dichotomy of nurse education. Karstadt, Lyn // British Journal of Nursing;8/14/2008, Vol. 17 Issue 15, p943 

    The article focuses on the report of Darzi "Next Stage Review" titled "A High Quality Workforce," which heralds a significant change in the investment in education for newly qualified nursing staff. Furthermore, a comprehensive scheme for allied health professionals will enable individuals to...

  • Barriers to education of overseas doctors in paediatrics: a qualitative study in South Yorkshire. Mahajan, J.; Stark, P. // Archives of Disease in Childhood;Mar2007, Vol. 92 Issue 3, p219 

    Objective: To explore the factors that may influence the progress of doctors who come from the Indian subcontinent to train in paediatrics in the UK. Methods: Overseas doctors training in paediatrics in Rotherham, Sheffield and Doncaster participated in the study. Focus groups were used to...

  • Hypertension: Total related costs to top $63 billion.  // Drug Store News;8/28/2006, Vol. 28 Issue 10, p48 

    The article provides an overview of the performance of the anti-hypertension drug market in the United States. Data from the American Heart Association and the American Stroke Association showed that about 65 million adults in the U.S. have high blood pressure. Angiotensin II receptor blockers...

  • The silent killer. Martin, Kymberly // Australian Journal of Pharmacy;Feb2010, Vol. 91 Issue 1077, p30 

    The article discusses risk assessment factors for cardiovascular diseases, which the pharmaceutical industry in Australia must consider. It mentions that the best way to treat cardiovascular diseases is through absolute risk assessment instead of focusing on blood pressure treatment. It adds...

  • Education Trumps Regulation. Dutton, James E. // Pharmaceutical Executive;Mar2008, Vol. 28 Issue 3, p102 

    The author reflects on the implementation of the SafeRx Act legislation requiring licensure among pharmaceutical sales representatives in Washington D.C. He assesses the need for sales representatives to know the basic principles of drug actions and interactions, drug-resistance trends, and...

  • Hinds CC, Hinds supervisors swap leads to expanded nursing/allied health center.  // Jackson Advocate;9/25/2014, Vol. 76 Issue 51, p8A 

    The article focuses on the move of Hinds Community College (CC) in Jackson, Mississippi to swap acres of property and buildings with the Hinds County Board of Supervisors for the expansion of the programs and teaching laboratories at the college's Campus-Nursing/Allied Health Center (NAHC).

  • Higher Learning. Agro, Brittany // Pharmaceutical Executive;May2009, Vol. 29 Issue 5, p20 

    The article reports on the new educational initiative for hypertension and related cardiovascular disease by the American Society of Hypertension (ASH) in the U.S. As stated, it is made to heighten the level of education to unite health professionals and pharmaceutical sales representatives....

  • Strong potential for cross risk-factor single pill therapies.  // PharmaWatch: Monthly Review;August 2004, Vol. 3 Issue 8, p15 

    Recently published data from the Genetic Epidemiology Network of Arteriopathy (GENOA) study has demonstrated that dyslipidemia is highly prevalent in hypertensive adults and that this condition is insufficiently treated in more than half of the cases. As Datamonitor's Laurent Chanroux explains,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics